Jason Butler
Stock Analyst at Citizens
(4.77)
# 168
Out of 5,176 analysts
141
Total ratings
52.83%
Success rate
60.81%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Market Outperform | $88 → $96 | $62.39 | +53.87% | 18 | Feb 25, 2026 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $3.19 | +150.78% | 2 | Jan 5, 2026 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $2.76 | +588.41% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $110.70 | +18.34% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $9.31 | +104.08% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $63.24 | +45.48% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.21 | +185.04% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $28.88 | -3.05% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $22.01 | +68.11% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $13.65 | +185.71% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.10 | +93.55% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $21.97 | +355.17% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $28.35 | +34.04% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $9.13 | +97.15% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.76 | +44.93% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $697.05 | +0.57% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.18 | +183.02% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.61 | +187.44% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.10 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $9.27 | +452,974.43% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $12.17 | +853.16% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.53 | +98.68% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.40 | - | 1 | Dec 2, 2020 |
Cytokinetics
Feb 25, 2026
Maintains: Market Outperform
Price Target: $88 → $96
Current: $62.39
Upside: +53.87%
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $3.19
Upside: +150.78%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $2.76
Upside: +588.41%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $110.70
Upside: +18.34%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $9.31
Upside: +104.08%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $63.24
Upside: +45.48%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.21
Upside: +185.04%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $28.88
Upside: -3.05%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $22.01
Upside: +68.11%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $13.65
Upside: +185.71%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.10
Upside: +93.55%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $21.97
Upside: +355.17%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $28.35
Upside: +34.04%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $9.13
Upside: +97.15%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.76
Upside: +44.93%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $697.05
Upside: +0.57%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.18
Upside: +183.02%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $6.61
Upside: +187.44%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.10
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $9.27
Upside: +452,974.43%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $12.17
Upside: +853.16%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.53
Upside: +98.68%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $2.40
Upside: -